NVAX

#2093
Novavax, Inc. - Common Stock
11.0 9 USD
+7.46%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
10.89
11.19
年范围
6.13
11.97
日变化
+7.46%
每月变动
+38.45%
6个月变化
+61.90%
年变化
+56.64%
前一天收盘价
10.3 2
Open
10.9 4
最低价
10.8 9
High
11.1 9
交易量
1 399
展开完整图表 完整图表

Financials

概览 声明 统计 股息
每季度 年度
  • Market Capitalization 1.82 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry 生物技术
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
2.6
市销率
1.04

Novavax, Inc. - Common Stock

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

新闻